Overall, our results highlight how treatment with SGLT2 inhibitors can be a valid therapeutic choice to delay and potentially prevent the progression of renal dysfunction and hepatic damage in patients with T2DM and CTP B cirrhosis. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.